Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the ...

The EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC) ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the first drug in the class available in both intravenous and subcutaneous ...

J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth. In a new podcast, web editor Nicole Raleigh speaks ...

Tremfya, developed by J&J ... authorisation to include treatment for moderately to severely active Crohn's disease, with a decision expected later in 2025.

Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

adults with moderately to severely active ulcerative colitis. adults with moderately to severely active Crohn’s disease. Tremfya is approved in Europe, Canada, Japan, and a number of other countries ...

Now moving on to immunology, I draw your attention to the recent FDA approval of TREMFYA in Crohn's disease, our fourth indication for TREMFYA. TREMFYA is currently the only IL-23 inhibitor with ...

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q1 CY2025, with ...